Monday, July 18, 2022 | Kaiser Health News

Melanoma kills almost twice as many men as women: study

Researchers in London have found that skin cancer deaths in men have increased by 219% since 1973, compared to 76% in women over the same period. Meanwhile, a separate study found that black and Latino cancer patients experienced more delays in care than white patients. Other searches cover covid, menstruation, Alzheimer’s, and more.

Fox News: Skin cancer deaths in men higher than women: new analysis

Cancer Research UK – an independent cancer research organization in London – reviewed records of skin cancer deaths. The group found that male melanoma skin cancer deaths have increased 219% since 1973. (Moore, 7/17)

CIDRAP: cancer treatment delays highlighted in minority groups amid COVID-19

A higher proportion of black (75.6%) and Latino (80.2%) participants and those of other races (75.9%) experienced changes in care, including delays in clinic visits, laboratory tests and imaging, as well as a change in place of care compared to White participants (57.1%). A higher proportion of black respondents (98.0%) than white respondents (84.1%) who had changes in care said that their clinic or doctor requested the changes. (7/15)

On covid research news —

The New York Times: Covid-19 vaccines temporarily altered menstrual cycles, study finds

Almost half of participants in a recent study who menstruated regularly at the time of the survey reported heavier bleeding during their periods after receiving the Covid-19 vaccine. Others who usually didn’t menstruate – including transgender men, people on long-acting contraceptives and postmenopausal women – also experienced unusual bleeding. (Sheikh, 07/15)

CBS News: Studying the effects of a long COVID

Since contracting COVID-19 in January 2021, Ken Todd has never fully recovered, making him one of the millions who suffer from “long COVID”. (7/17)

CIDRAP: More Side Effects (Mostly Mild) When Flu Shot Is Given With COVID Booster

Self-reported data from nearly one million Americans show 8% to 11% higher rate of mostly mild systemic adverse events after seasonal flu vaccine and COVID mRNA booster doses -19 (third) than with the COVID-19 booster alone. (Van Beusekom, 7/15)

In news about other research —

CIDRAP: A study shows a global increase in mycoplasma pneumoniae resistant to macrolides

Antibiotic resistance, one of the most common causes of community-acquired pneumonia (CAP) in children, has increased dramatically over the past two decades, according to research published this week in JAMA Network Open. To analyze global patterns, temporal trends, and regional variations in macrolide-resistant Mycoplasma pneumoniae (MRMP) infections, a team of South Korean researchers conducted a systematic review and meta-analysis of 153 studies from 150 papers. published before September 10, 2021. (7/15)

Zenger News: One glass of wine a day may lead to Alzheimer’s disease, research finds

Just one small glass of wine a day could give you Alzheimer’s or Parkinson’s disease, according to new research. Consuming just seven units of alcohol a week – half the recommended maximum – fuels iron in the brain. (Kitanovska, 07/16)

AP: High-flying experiment: do stem cells grow better in space?

Researcher Dhruv Sareen’s own stem cells are now orbiting the Earth. The mission? To test if they grow better in weightlessness. Scientists at Cedars-Sinai Medical Center in Los Angeles are trying to find new ways to produce huge batches of a type of stem cell that can generate almost any other type of cell in the body – and potentially be used to make treatments for many diseases. The cells arrived at the International Space Station this weekend on a supply ship. (Ungar, 07/17)

Also, in innovations —

The Wall Street Journal: High-tech smell sensors aim to detect diseases, explosives and even moods

But now scientists and entrepreneurs are redoubling their efforts to recreate the sense of smell in compact devices that detect and analyze odors in the same way that cameras now recognize our faces and microphones our words. In search of these high-tech devices – which could use smells to detect diseases like cancer or Covid-19, locate hidden explosives or decipher our moods and behaviors – some companies are taking advantage of advances in synthetic biology and genetic engineering. Others exploit advances in artificial intelligence. (Hernández, 07/16)

Reuters: Roche launches dual antigen and antibody diagnostic test for hepatitis C

Roche (ROG.S) has launched a new dual antigen and antibody diagnostic test for hepatitis C, the Swiss pharmaceutical company announced on Monday, which it says will give earlier diagnosis of the virus. The Elecsys HCV Duo is the first commercially available immunoassay that allows simultaneous and independent determination of hepatitis C virus status from a single sample of human plasma or serum. (7/18)

Comments are closed.